Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ziopharm Oncology Achieves Positive Results for Glioblastoma Treatment | Contract Pharma

What are you searching for?

Sign in

Ziopharm Oncology Achieves Positive Results for Glioblastoma Treatment

Controlled IL-12 platform appears to have activity as a monotherapy and is now being studied in an expanded group of patients

By: Cassandra Gervolino

Ziopharm Oncology Inc. presented new interim analyses of clinical data from two ongoing sub-studies in its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination with a PD-1 inhibitor, for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults.
 “Profiling an expanded number of patients with rGBM shows that Controlled IL-12 engages patients’ immune systems which we previously showed was an indicator of improved overall survival,” said Laurence Cooper, M.D., Ph.D., CEO of Ziopharm. “Furthermore, we demonstrate that Controlled IL-12 can be combined with a PD-1 inhibitor and the initial data from this phase 1 trial are consistent with immune-mediated anti-tumor effects with a favorable safety profile. As the follow up from these sub-studies continues, we remain encouraged by the application of Controlled IL-12 as monotherapy and the combination data support our plans to initiate a phase 2 trial combining Controlled IL-12 with a second PD-1 inhibitor in the next few weeks.” 
                   
“Glioblastoma is a devastating brain cancer with few treatment options demonstrating success and a significant need for new treatment options. The Controlled IL-12 platform that appears to have activity as monotherapy is now being studied in an expanded group of patients and the new data confirms that combining Controlled IL-12 with PD-1 inhibitor is a rational combination. The encouraging safety and efficacy data previously observed in monotherapy may be enhanced with immune checkpoint inhibitors to engage the body’s own immune system to generate an anti-tumor response against recurrent glioblastoma,” said Dr. Antonio Chiocca, M.D., Ph.D., poster author and Professor of Neurosurgery at Harvard Medical School, Surgical Director of the Center for Neuro-oncology at Dana-Farber Cancer Institute, and Chairman of Neurosurgery and Co-Director of the Institute for the Neurosciences at Brigham and Women’s Hospital.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters